NCT02452879 Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Efficacy Study Status UNKNOWN Phase NA
NCT02447367 Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers Status COMPLETED Phase PHASE1
NCT02396160 The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence Status COMPLETED Phase NA
NCT02386072 A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) Status COMPLETED Phase N/A
NCT02377765 Use of Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) in Maintaining OAB Symptoms Improvement. Status COMPLETED Phase NA
NCT02335853 Association Between Metabolic Syndrome and Serum Nerve Growth Factor Levels in Women With Overactive Bladder Status UNKNOWN Phase N/A
NCT02327936 Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children Status COMPLETED Phase PHASE3
NCT02320773 A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice Status COMPLETED Phase N/A
NCT02315950 The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder Status RECRUITING Phase NA
NCT02297178 A Follow-net Investigation of a Randomised Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding Status WITHDRAWN Phase N/A
NCT02279615 Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia. Status UNKNOWN Phase PHASE4
NCT02271607 The Effect and Safety of Moxibustion Therapy for Overactive Bladder Patients Status COMPLETED Phase NA
NCT02251054 Virtual Avatar Coaches for Behavioral Therapy of Patients With Overactive Bladder Status COMPLETED Phase NA
NCT02240459 A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment Status COMPLETED Phase PHASE2
NCT02211846 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder Status COMPLETED Phase PHASE1